Leo Varadkar (Dublin West, Fine Gael) | Oireachtas source

There is a detailed agreement with the IPHA on the assessment times and when they can stop and start again. It is always open to pharmaceutical companies to come in with new evidence or more evidence as to why a product is effective. It is always open for them to come in with a new price. It is always possible to introduce new options, for example, cost-sharing options where the HSE only pays when the drug works, not in the 10 or 11 cases where it does not, or other agreements similar to that. They are all options that are open.

I think I have covered pretty much everything.